Purpose/Objective(s): Previous studies have shown similar clinical outcome between single or multi-fraction (Fr) radiation therapy for MSCC patients with poor prognosis whereas patients with expected longer survival may require long course radiation therapy to prevent local failure. However, such poor risk group has not yet been clearly identified for daily clinical practice. We examined if the known predictive Tokuhashi scoring system could be adapted in MSCC patients treated with palliative radiation therapy. Materials/Methods: A retrospective review of the treatment outcome of the MSCC patients who received palliative radiation therapy from January 2014 to May 2015 was conducted. The patients were stratified by the Tokuhashi scoring system into group 1(score < 9): expected survival < 6 months, and group 2(score > or equal 9): expected survival > 6 months. Their survival was tested against subsequent systemic therapy (chemotherapy, targeted or hormonal therapy) and other risk factors including age, primary site, visceral metastasis, baseline motor function, prior radiation therapy, radiation therapy fraction (single or multiple). Results: The outcome of 119 patients was studied, 100 (84%) patients have already succumbed. The overall median survival was 55 days (range 4 to 576 days). 93 patients (78.2%) belonged to group 1. The median dose delivered was 25 Gy in 5 Frs (range: 7 Gy in 2 Frs to 40 Gy in 10 Frs<to cauda equina>). Only 9 patients (7.6%) received singlefraction radiation therapy, all belonging to group 1. Patients belonging to Tokuhashi group 1 had shorter median survival than group 2; 49 and 108 days respectively (P Z 0.02).Among all the patients, subsequent systemic treatment (Hazard ratio [HR] Z 0.354, 95% CI 0.194-0.647, P Z 0.01) and non-visceral metastasis (HR Z 0.593, 95% CI 0.363-0.968, P Z 0.037) were associated with better survival in multivariate analysis. For patients in group 1, primary breast or prostate cancer (HR Z 0.260, 95% CI 0.109-0.620, P Z 0.002) or lung cancer (HR Z 0.425, 95% CI 0.246-0.734, P Z 0.002), non-visceral metastasis (HR Z 0.426, 95% CI 0.236-0.771, P Z 0.0048), multi-fraction (HR Z 0.462, 95% CI 0.218-0.982, P Z 0.0447) and subsequent systemic therapy (HR Z 0.424, 95% CI 0.217-0.828, P Z 0.012) were associated with better survival. The survival of a subset of patients in group 1 without subsequent systemic therapy was dismal (median survival only 40 days) and not altered by radiation therapy schedule (P Z 0.198). Conclusion: MSCC comprises of a very heterogeneous group of patients, even under the Tokuhashi grouping, systemic therapy or visceral metastasis may be more important prognostic factors. Further studies are necessary to better select the poor risk group. In clinical practice, singlefraction radiation therapy could be considered in Tokuhashi group 1 patients due to expected short survival, especially those without reasonable systemic treatment options.
Purpose/Objective(s): Previous studies have shown similar clinical outcome between single or multi-fraction (Fr) radiation therapy for MSCC patients with poor prognosis whereas patients with expected longer survival may require long course radiation therapy to prevent local failure. However, such poor risk group has not yet been clearly identified for daily clinical practice. We examined if the known predictive Tokuhashi scoring system could be adapted in MSCC patients treated with palliative radiation therapy. Materials/Methods: A retrospective review of the treatment outcome of the MSCC patients who received palliative radiation therapy from January 2014 to May 2015 was conducted. The patients were stratified by the Tokuhashi scoring system into group 1(score < 9): expected survival < 6 months, and group 2(score > or equal 9): expected survival > 6 months. Their survival was tested against subsequent systemic therapy (chemotherapy, targeted or hormonal therapy) and other risk factors including age, primary site, visceral metastasis, baseline motor function, prior radiation therapy, radiation therapy fraction (single or multiple). Results: The outcome of 119 patients was studied, 100 (84%) patients have already succumbed. The overall median survival was 55 days (range 4 to 576 days). 93 patients (78.2%) belonged to group 1. The median dose delivered was 25 Gy in 5 Frs (range: 7 Gy in 2 Frs to 40 Gy in 10 Frs<to cauda equina>). Only 9 patients (7.6%) received singlefraction radiation therapy, all belonging to group 1. Patients belonging to Tokuhashi group 1 had shorter median survival than group 2; 49 and 108 days respectively (P Z 0.02).Among all the patients, subsequent systemic treatment (Hazard ratio [HR] Z 0.354, 95% CI 0.194-0.647, P Z 0.01) and non-visceral metastasis (HR Z 0.593, 95% CI 0.363-0.968, P Z 0.037) were associated with better survival in multivariate analysis. For patients in group 1, primary breast or prostate cancer (HR Z 0.260, 95% CI 0.109-0.620, P Z 0.002) or lung cancer (HR Z 0.425, 95% CI 0.246-0.734, P Z 0.002), non-visceral metastasis (HR Z 0.426, 95% CI 0.236-0.771, P Z 0.0048), multi-fraction (HR Z 0.462, 95% CI 0.218-0.982, P Z 0.0447) and subsequent systemic therapy (HR Z 0.424, 95% CI 0.217-0.828, P Z 0.012) were associated with better survival. The survival of a subset of patients in group 1 without subsequent systemic therapy was dismal (median survival only 40 days) and not altered by radiation therapy schedule (P Z 0.198). Conclusion: MSCC comprises of a very heterogeneous group of patients, even under the Tokuhashi grouping, systemic therapy or visceral metastasis may be more important prognostic factors. Further studies are necessary to better select the poor risk group. In clinical practice, singlefraction radiation therapy could be considered in Tokuhashi group 1 patients due to expected short survival, especially those without reasonable systemic treatment options. Purpose/Objective(s): Cerebral arteriovenous malformation (AVM) is defined as an abnormal collection of vessels with multiple enlarged feeder arteries and dilated venous outflow, associated with risks of blood shunting and hemorrhage. Our center had previously used CT angiogram and magnetic resonance angiogram for localization of AVMs for linear accelerator based radiosurgery using a frameless radiosurgery combined with the decoupled treatment steps. Utilizing a phantom model, we demonstrated that 3DRA offered better accuracy compared to digital angiography orthogonal image pairs (0.27AE0.14 mm versus 0.39AE0.15 mm, respectively). Given this geometric accuracy, in 2009 we transitioned to 3DRA. To date, we have treated over 40 AVMs with this technique. We have previously reported early clinical data, but are now able to more substantially report on clinical response with this modality. Materials/Methods: From 2010 to 2011, 22 cases were identified with follow up of at least 2 years after initial SRS date. Patients were seen in routine follow-up with serial imaging. Angiogram was repeated (either conventional or 3DRA) after appropriate time elapsed per clinician judgment. Chart and imaging review was conducted to assess response. Angiograms were reviewed with the assistance of our 3DRA interventional radiology expert. Results: We have updated our existing series to include 22 AVMs (19 patients). Initial treatment included embolization for 4, craniotomy for hematoma evacuation for 2, and decompression with drain or ventriculostomy for 3 cases. Spetzler-Martin grades included four grade 1, eight grade 2, eight grade 3, and one grade 4. SRS pre-treatment volume ranged from 0.035 to 27.3cc, although majority had volumes 4cc. Patients were given single fraction SRS, with doses ranging from 1556 to 2250 cGy prescribed to isocenter (with 1400 to 2000 to the 80%) using 4-5 arcs. Overall, 16 cases (72%) had complete resolution of AVM, one had stable sized lesion and five had smaller lesions. No patients experienced additional hemorrhage in the interval following SRS, but one patient was sent for embolization due to presence of residual AVM (this patient had second largest AVM in the series, 22.3cc). The patient with the largest AVM in the series (27.3cc) had resolution on scan done 4.3 years after treatment. Conclusion: Our results from patients treated with frameless SRS using high-resolution 3DRA and commercially available stereotactic radiosurgery treatment planning found patients to have either complete resolution or decrease in size of lesions treated. We will continue to follow patients who have not yet had resolution to see whether their lesions will continue to evolve. Our results suggest good geometric accuracy using 3DRA technique, given the small size of most of the lesions treated. outcome in studies of stereotactic radiosurgery (SRS) for vestibular schwannomas. In this study, we investigated whether an inherent functional relationship exists among these dose surrogates and its analytical formalism and expressions. Materials/Methods: A cohort of 97 serial patient cases treated with single-fraction stereotactic radiosurgery at our institution from 2007-2013 was reviewed and 85 cases were found to be analyzable, excluding cases such as surgically absent cochlea, incomplete visualization of the structure, etc. For all the cases, the mean prescription dose was 12.5 AE 0.3 Gy (range, 12-13 Gy) and mean target volume 1.32 AE 1.51 mL 
